Literature DB >> 29085505

Diagnostic value of serum bile acid composition patterns and serum glycocholic acid levels in cholangiocarcinoma.

Siriporn Proungvitaya1,2, Sutthikan Sombattheera1,2, Patcharee Boonsiri3, Temduang Limpaiboon1,2, Sopit Wongkham2, Chaisiri Wongkham2, Attapol Titapun2,4, Tanakorn Proungvitaya1,2.   

Abstract

Cholangiocarcinoma (CCA) is a cancer of biliary epithelial cell origin, which is prevalent in northeastern Thailand. The majority of patients with CCA are diagnosed at the advanced-stage of the disease. Although the early detection and diagnosis of CCA is critical to improve the prognosis of patients, there are presently no specific tumor markers for CCA. A previous study demonstrated that the total serum bile acid (TSBA) levels of patients with CCA are significantly increased, compared with those of healthy controls. In addition, although statistically insignificant, the TSBA levels in the sera of patients with CCA tended to be increased, as compared with the sera of patients with benign biliary disease (BBD). In the present study, the high performance liquid chromatographic (HPLC) patterns of bile acid composition were compared in the sera of patients with CCA, patients with BBD and normal controls. The results revealed that serum bile acid patterns in patients with CCA varied, compared with those in patients with BBD and normal controls. As hypothesized, glycocholic acid (GCA) levels in the sera of patients with CCA and BBD were high, compared with those in healthy controls. In addition, GCA levels in the sera of patients with CCA tended to be higher, as compared with patients with BBD; however, this result was not statistically significant. Therefore, determination of the bile acid patterns and GCA levels in sera using HPLC is feasible, and may aid the diagnosis of CCA.

Entities:  

Keywords:  cholangiocarcinoma; serum bile acid; serum glycocholic acid

Year:  2017        PMID: 29085505      PMCID: PMC5649624          DOI: 10.3892/ol.2017.6763

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  15 in total

1.  Bile acid profiling in human biological samples: comparison of extraction procedures and application to normal and cholestatic patients.

Authors:  Lydie Humbert; Marie Anne Maubert; Claude Wolf; Henri Duboc; Myriam Mahé; Dominique Farabos; Philippe Seksik; Jean Maurice Mallet; Germain Trugnan; Joëlle Masliah; Dominique Rainteau
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-05-17       Impact factor: 3.205

Review 2.  Separation techniques for bile salts analysis.

Authors:  A Roda; F Piazza; M Baraldini
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-10-09

3.  Determination of free bile acids in pharmaceutical preparations by packed column supercritical fluid chromatography.

Authors:  S Scalia; D E Games
Journal:  J Pharm Sci       Date:  1993-01       Impact factor: 3.534

4.  Quantification of the 15 major human bile acids and their precursor 7α-hydroxy-4-cholesten-3-one in serum by liquid chromatography-tandem mass spectrometry.

Authors:  Carine Steiner; Arnold von Eckardstein; Katharina M Rentsch
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-09-09       Impact factor: 3.205

Review 5.  Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos.

Authors:  Banchob Sripa; Jeffrey M Bethony; Paiboon Sithithaworn; Sasithorn Kaewkes; Eimorn Mairiang; Alex Loukas; Jason Mulvenna; Thewarach Laha; Peter J Hotez; Paul J Brindley
Journal:  Acta Trop       Date:  2010-07-23       Impact factor: 3.112

Review 6.  [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].

Authors:  Rolf Olsson
Journal:  Lakartidningen       Date:  2002-03-21

Review 7.  The role of bile acids in carcinogenesis.

Authors:  P R Debruyne; E A Bruyneel; X Li; A Zimber; C Gespach; M M Mareel
Journal:  Mutat Res       Date:  2001-09-01       Impact factor: 2.433

8.  Serum unconjugated primary and secondary bile acids in patients with cholangiocarcinoma and hepatocellular carcinoma.

Authors:  S Changbumrung; R Tungtrongchitr; P Migasena; S Chamroenngan
Journal:  J Med Assoc Thai       Date:  1990-02

9.  Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways.

Authors:  Gianfranco Alpini; Noriatsu Kanno; Jo Lynne Phinizy; Shannon Glaser; Heather Francis; Silvia Taffetani; Gene LeSage
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-12-30       Impact factor: 4.052

Review 10.  Liver fluke induces cholangiocarcinoma.

Authors:  Banchob Sripa; Sasithorn Kaewkes; Paiboon Sithithaworn; Eimorn Mairiang; Thewarach Laha; Michael Smout; Chawalit Pairojkul; Vajaraphongsa Bhudhisawasdi; Smarn Tesana; Bandit Thinkamrop; Jeffrey M Bethony; Alex Loukas; Paul J Brindley
Journal:  PLoS Med       Date:  2007-07       Impact factor: 11.069

View more
  2 in total

1.  Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma.

Authors:  Elisa Herraez; Marta R Romero; Rocio I R Macias; Maria J Monte; Jose J G Marin
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

Review 2.  Current and future roles of mucins in cholangiocarcinoma-recent evidences for a possible interplay with bile acids.

Authors:  Elisa Danese; Andrea Ruzzenente; Martina Montagnana; Patricia Marie-Jeanne Lievens
Journal:  Ann Transl Med       Date:  2018-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.